ZEN Graphene Solutions Develops Graphene-Based Ink with 99% Virucidal Activity against COVID-19

 $Z \equiv N$

ZEN Graphene Solutions Ltd. (TSX.V: ZEN)

Report that after 5 months of optimization, it has developed a novel graphene-based virucidal ink with 99% effectiveness against COVID-19.

ZEN's Virucidal ink was still 99% effective a minimum of 35 days after application to N95 mask material.



ZEN Graphene Solutions Develops Graphene-Based Ink with 99% Virucidal Activity against COVID-19

September 22, 2020

Guelph, ON

September 22, 2020

ZEN Graphene Solutions Ltd. ("ZEN" or the "Company") (TSXV:ZEN and OTC:ZENYF) is pleased to report that after 5 months of optimization, it has developed a novel graphene-based virucidal ink with 99% effectiveness against COVID-19.

Highlights:

- ZEN's Virucidal ink is 99% effective against the COVID-19 virus
- ZEN's Virucidal ink was still 99% effective a minimum of 35 days after application to N95 mask material
- ZEN is now developing plans to expedite commercialization of this product, pending regulatory approval.
- ZEN has filed a provisional patent for this graphene-based virucidal product
- ZEN invites PPE companies to reach out for potential partnerships to bring this new technology to market: Antiviralink@ZENGraphene.com
- ZEN is beginning antibacterial and antifungal tests utilizing its proprietary ink formulation

The company has received results from the latest round of testing of its proprietary, virucidal graphene-based ink formulation at Western University's ImPaKT facility Biosafety Level 3 laboratory. Two graphene-based ink samples at different concentrations were applied to N95 mask filtration media and then exposed to the SARS-CoV-2 virus that causes COVID-19 and tested for antiviral properties in accordance with ISO 18184:2019. Very significant virucidal activity was recorded and reported, achieving 99% inactivation of the virus for both samples in 3 separate tests each and verified through a second round of testing. Of significance, the antiviral effect of the second round of testing was on material that was prepared 35 days earlier demonstrating the ongoing virucidal activity of ZEN's proprietary ink. For those interested in seeing the report, please contact the company directly.

The research and development of this antiviral ink formulation was conducted entirely by ZEN's research team at its Guelph, Ontario facility using a graphene product that was produced from its Albany PureTM Graphite.

ZEN is now developing plans to bring this novel virucidal ink to commercial production including working with regulatory authorities and government agencies to fast track this product to Canadian and global markets to help the fight against the Coronavirus pandemic. ZEN is expanding the testing of this graphene-based ink formulation to include pathogenic bacteria and fungi and will report on these tests as soon as the results are available.

CEO Dr. Francis Dube commented, "These recent results have

dramatically exceeded our expectations with our ink achieving 99% virucidal activity against the SARS-CoV-2 virus 35 days after production of the samples. I am very proud of our Research and Development team for their exceptional work in developing this novel formulation. We are excited about the role our ink can play in the fight against this global pandemic and are moving quickly to mobilize our resources to bring this product to market."

For companies interested in adding this antiviral ink to their personal protective equipment manufacturing or other potential commercial applications, please send us an email at antiviralink@zengraphene.com. ZEN Graphene Solutions is seeking advanced applied graphene-related research projects where ZEN could support this research by providing customized graphene materials and, in some cases, funding in exchange for some commercialisation rights to be negotiated.

Please submit your proposals in confidence to researchproposals@ZENGraphene.com

Disclaimer

The company is not making any express or implied claims that its products have the ability to cure or contain the COVID 19 virus at this time.

About ZEN Graphene Solutions Ltd.

ZEN is an emerging graphene technology solutions company with a focus on the development of graphene-based nanomaterial products and applications. The unique Albany Graphite Project provides the company with a potential competitive advantage in the graphene market as independent labs in Japan, UK, Israel, USA and Canada have independently demonstrated that ZEN's Albany PureTM Graphite is an ideal precursor material which easily converts (exfoliates) to graphene, using a variety of mechanical, chemical and electrochemical methods.

For further information:

Dr. Francis Dubé, Chief Executive Officer

andrew@city-investors-cirlcle.com

City Investors Circle is based in the financial district of the City of London.

We present selected interesting and exciting junior mining companies listed on the ASX, TSX, and TSX Venture exchanges, to a group of city professionals, brokers, HNWI's, and private investors, all of whom are active investors, with a mandate to invest in junior mining companies.

Our audience is selected and individually invited, to ensure interest and relevance.

Meetings are small group, highly focused and engaged, with a lively Q and A to follow the main presentation.

We create awareness, and maintain interest in presenting companies by disseminating their future news to our entire investor group via email, social media, and our monthly newsletter.

If you wish to present to our select group of active mining investors, please email: andrew@city-investors-circle.com for information.

Disclosure

Disclosure: I have no position in ZEN.

The writer is not a Registered Investment Advisor or Financial Planner. This article is for informational purposes only. It does not constitute an offer to sell, a solicitation to buy, or a recommendation regarding any securities transaction.

The information contained in this writing should not be construed as financial or investment advice on any subject matter.

All the information used in the preparation of articles on the Site has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of such information.

You should always consult an investment professional.